Novartis’ Sandoz spinoff is right around the corner, and, to celebrate the occasion, the Swiss pharma is plotting a special stock distribution scheme.
Roughly a year after disclosing plans to spin off Sandoz, Novartis says the separation of its generics and biosimilars business is set to take place on or around Oct. 4.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,